Implantable cardioverter-defibrillators for secondary prevention: is it worth it in the elderly?

Area of Science:

• Cardiology
• Geriatrics
• Biomedical Engineering

Background:

• Aging leads to cardiac structural changes, increasing the risk of fatal ventricular arrhythmias in older adults.
• Sudden cardiac death disproportionately affects individuals aged 65 and older.
• The growing elderly population necessitates effective management strategies for malignant ventricular arrhythmias.

Purpose of the Study:

• To review and summarize data on the efficacy and appropriateness of implantable cardioverter-defibrillators (ICDs) for secondary prevention of cardiac arrest in elderly patients.
• To address physician reluctance in implanting ICDs in older individuals despite proven benefits.

Main Methods:

• Review of clinical outcome trials and existing literature on ICD use in the elderly population.
• Analysis of data regarding mortality reduction, safety, and economic advantages of ICD therapy for secondary prevention.

Main Results:

• Implantable cardioverter-defibrillators (ICDs) significantly improve overall survival in patients receiving secondary prevention for cardiac arrest compared to pharmacologic therapy.
• ICD use for secondary prevention is associated with reduced all-cause mortality in older adults.
• The economic impact of ICD therapy in the elderly population appears favorable.

Conclusions:

• Current evidence does not support withholding ICD therapy from elderly patients based solely on age.
• ICD implantation is a safe and effective strategy for secondary prevention of cardiac arrest in older adults.
• Physicians should consider ICDs for eligible elderly patients to improve survival and manage ventricular arrhythmias.